长春高新(000661.SZ)：金赛药业GS3-007a干混悬剂的境内生产药品注册临床试验申请获得批准

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial application of GS3-007a, a growth hormone secretagogue intended for treating pediatric growth hormone deficiency (PGHD) [1] Company Summary - Changchun Jinsai Pharmaceutical has developed GS3-007a, an oral small molecule growth hormone secretagogue, which is classified as a Class 1 chemical drug [1] - The approval of the clinical trial application is expected to facilitate the clinical development of GS3-007a and address unmet clinical needs for patients [1] Industry Summary - Currently, there are no similar products available in the domestic market for the treatment of PGHD, indicating a potential market opportunity for GS3-007a [1]